PRX-100 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Presbyopia
Conditions
Presbyopia
Trial Timeline
Sep 1, 2015 → Nov 1, 2015
NCT ID
NCT02554396About PRX-100 + Placebo
PRX-100 + Placebo is a phase 2 stage product being developed by LENZ Therapeutics for Presbyopia. The current trial status is completed. This product is registered under clinical trial identifier NCT02554396. Target conditions include Presbyopia.
What happened to similar drugs?
1 of 6 similar drugs in Presbyopia were approved
Approved (1) Terminated (1) Active (5)
🔄Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Placebo (Vehicle) ophthalmic solutionLENZ TherapeuticsPhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic SolutionLENZ TherapeuticsPhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + VehicleLENZ TherapeuticsPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02554396 | Phase 2 | Completed |
Competing Products
14 competing products in Presbyopia